WASHINGTON, DC, Oct. 3 – Psychiatric Genomics anticipates closing a Series B round of financing worth between $20 million and $25 million later in the current quarter, the company’s president and CSO told GenomeWeb on Wednesday. 

Michael Palfreyman, who is also Psychiatric Genomics’ founder, could not say what fund will be leading the round, but said that Oxford Bioscience, which led the company’s Series A round, will be a participant.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.